A number of new antidiabetic medications have been launched in recent years. However, these are more expensive than standard treatments until they come off patent. Doctors are under pressure to keep costs down and this is reflected in the current NICE guidelines. This article examines the issue of cost-effectiveness when treating the elderly patient with diabetes.